Bio-Rad Laboratories, Inc.
NYSE · us_market
No AI summary generated yet for this ticker.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
On May 18, 2026, Elliott Investment Management disclosed a significant stake in Bio-Rad Laboratories and began pressing for changes to improve shareholder outcomes, focusing in part on the company’s large holding in Sartorius, valued at about US$5.00 billion. An interesting angle is that the market now values Bio-Rad’s Sartorius stake at nearly the company’s entire market value, raising questions about how much credit investors are giving to Bio-Rad’s core operating business. With Elliott’s...
Elliott reportedly built a sizable Bio-Rad stake as the life-science tools supplier trades far below its late-2021 peak.
Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SP
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund reported strong first-quarter performance for its Ariel Focus Fund, which gained 7.30%, significantly outperforming both the S&P 500’s -4.33% return and the Russell 1000 Value Index’s 2.10% gain amid […]
Biocon’s fair value estimate has been trimmed slightly from ₹420.74 to about ₹416.53, signalling a modest reset in how analysts are sizing up the stock today. That shift lines up with a broader, more cautious tone in recent research on life sciences companies, where execution risk, revenue trajectories and the market’s willingness to pay up after guidance disappointments are under close review. As you read on, you will see how these moving pieces shape the evolving Biocon narrative and what...
Today, we will review the second quarter 2025 financial results and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer; Jon Jonathan DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer.
Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Ruben Argueta: Thank you, Regina. My name is Ruben Argueta, Bio-Rad's new Head of IR. Today, we will review the financial results for the first quarter ended March 31, 2026, and provide an update on key business trends for Bio-Rad.
Moby summary of Bio-Rad Laboratories, Inc.'s Q1 2026 earnings call
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2019-08-01 | 1.32 | 1.57 | +18.94% |
| 2019-05-08 | 1.14 | 1.65 | +44.74% |
| 2019-02-28 | 1.86 | 2.13 | +14.52% |
| 2018-11-01 | 1.18 | 0.91 | -22.88% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BIO-B | +1.57% | +13.11% | -2.11% | +21.62% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -1.40% | +17.75% | +1.34% | +8.93% |